Immunic， Inc.宣布拟进行的公开发行-动脉网

Immunic, Inc. Announces Proposed Public Offering

CISION 等信源发布 2025-05-29 04:02



可切换为仅中文







NEW YORK

纽约

，

May 28, 2025

2025年5月28日

/PRNewswire/ --

/美通社/ --

Immunic, Inc.

Immunic有限公司

('Immunic' or the 'Company') (Nasdaq:

('Immunic' 或 '公司') (纳斯达克:

IMUX

), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has commenced an underwritten public offering of (i) pre-funded warrants to purchase shares of common stock, (ii) Series A warrants to purchase shares of common stock (or pre-funded warrants) expiring on .

)，一家正在开发用于慢性炎症和自身免疫性疾病的口服小分子治疗药物的生物技术公司，今日宣布已开始进行一项承销公开发行，内容包括（i）预融资认股权证以购买普通股，（ii）到期日为的A系列认股权证以购买普通股（或预融资认股权证）。

December 31, 2025

2025年12月31日

, (iii) and Series B warrants to purchase shares of common stock (or pre-funded warrants) expiring five years following the issuance date. The Series A and B warrants will immediately expire in proportion to the extent that the corresponding pre-funded warrant offered hereby is exercised on or prior to September 30, 2025, subject to certain exceptions.

，（iii）以及购买普通股（或预融资权证）的B系列权证，有效期为发行日起五年。A系列和B系列权证将立即按比例失效，前提是与此相关的预融资权证在2025年9月30日或之前已行使，但受某些例外情况的限制。

All of the securities to be sold in the proposed offering will be offered by Immunic. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering..

拟议发行中出售的所有证券将由Immunic提供。拟议发行受市场和其他条件的限制，无法保证发行是否或何时完成，也无法保证发行的实际规模或条款。

The Company intends to use the net proceeds received from the proposed offering to fund its clinical trials and operations and for other general corporate purposes.

公司打算将从拟议发行中获得的净收益用于资助其临床试验和运营，以及用于其他一般企业用途。

Leerink Partners is acting as the sole bookrunner for the offering.

Leerink Partners 是此次发行的唯一账簿管理人。

The offering is being made by Immunic pursuant to a shelf registration statement on Form S-3 (File No. 333-275717), as amended, initially filed with the Securities and Exchange Commission (the 'SEC') on

本次发行由Immunic依据表格S-3（文件编号333-275717）的储架注册声明进行，该声明经修订后最初于以下日期提交给美国证券交易委员会（“SEC”）：

November 22, 2023

2023年11月22日

, which became effective on

，于以下日期生效

May 31, 2024

2024年5月31日

. The offering is being made only by means of a preliminary prospectus supplement and the accompanying base prospectus that form a part of the registration statement. A preliminary prospectus supplement and the accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at .

此次发行仅通过初步招股说明书补充文件及作为注册声明一部分的附带基础招股说明书进行。与此次发行相关的初步招股说明书补充文件及附带基础招股说明书将提交给美国证券交易委员会（SEC），并将在SEC的网站上提供。

www.sec.gov

。

Copies of the preliminary prospectus supplement and the accompanying base prospectus, and when available, copies of the final prospectus supplement and the accompanying base prospectus relating to the offering, may be obtained by contacting Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, .

初步招股说明书补充文件和随附的基础招股说明书的副本，以及在可供获取时，与本次发行相关的最终招股说明书补充文件和随附的基础招股说明书的副本，可以通过联系Leerink Partners LLC，辛迪加部门，地址：州街53号，40楼获得。

Boston, MA

马萨诸塞州波士顿市

02109, or by telephone at (800) 808-7525 ext. 6105, or by email at

02109，或通过电话（800）808-7525分机6105，或通过电子邮件

syndicate@leerink.com

辛迪加@勒林克.康母

。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction..

本新闻稿不构成出售或征求购买要约，也不得在任何州或司法管辖区进行这些证券的销售，因为在该州或司法管辖区，此类要约、征求或销售在根据其证券法进行注册或资格认证之前是非法的。

About Immunic, Inc.

关于Immunic公司

Immunic, Inc. (Nasdaq:

Immunic有限公司（纳斯达克：

IMUX

输入多路复用器

) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple sclerosis, for which top-line data is expected to be available end of 2026.

是一家生物技术公司，正在开发用于治疗慢性炎症和自身免疫性疾病的临床管线，其疗法为口服小分子药物。该公司的主要开发项目——维多氟比钙（IMU-838）目前正处于治疗复发缓解型多发性硬化症的三期临床试验阶段，预计将在2026年底获得关键数据。

It has already shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and progressive multiple sclerosis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH).

它在复发缓解型多发性硬化症和进展型多发性硬化症患者的 2 期临床试验中已显示出治疗活性。Vidofludimus 钙通过其作为第一类核受体相关 1（Nurr1）激活剂的机制结合了神经保护作用，并通过选择性抑制二氢乳清酸脱氢酶（DHODH）发挥额外的抗炎和抗病毒作用。

IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management.

IMU-856靶向蛋白质Sirtuin 6（SIRT6），旨在恢复肠道屏障功能并再生肠上皮，这可能适用于多种胃肠道疾病，如乳糜泻、炎症性肠病、移植物抗宿主病以及体重管理。

IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases..

IMU-381目前正处于临床前测试阶段，这是一种正在开发的下一代分子，专门针对胃肠道疾病的需求。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警告性说明

This press release contains 'forward-looking statements' that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements.

本新闻稿包含“前瞻性声明”，这些声明涉及1995年《私人证券诉讼改革法案》所提供的安全港目的下的重大风险和不确定性。本新闻稿中所有关于策略、未来运营、未来财务状况、未来收入、预计费用、现金及现金跑道的充足性、临床试验的预期时间、进展和结果、前景、管理层计划与目标的声明，除历史事实陈述外，均为前瞻性声明。

Examples of such statements include, but are not limited to, statements relating to consummation of the proposed offering as well as the timing and size of the proposed offering, Immunic's development programs and the targeted diseases; the potential for vidofludimus calcium to safely and effectively target diseases; preclinical and clinical data for vidofludimus calcium; the feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the Company and further updates with respect thereto; and the development and commercial potential of any product candidates of the Company.

此类陈述的示例包括但不限于与拟议发行的完成、时间安排和规模相关的陈述，Immunic的研发计划及目标疾病；vidofludimus calcium在安全有效地针对疾病方面的潜力；vidofludimus calcium的临床前和临床数据；将vidofludimus calcium推进至多发性硬化症进展型的确证性第三阶段临床试验的可行性；当前和未来临床试验的时间安排以及预期的临床里程碑；公司的性质、战略和重点及与此相关的进一步更新；以及公司任何候选产品的开发和商业潜力。

Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties.

Immunic可能实际上无法实现前瞻性声明中披露的计划、意图或满足预期或预测，您不应过分依赖这些前瞻性声明。此类声明基于管理层的当前预期，涉及重大风险和不确定性。

Actual results and performance could differ materially from those projected in the forward-looking statements as a result of.

实际结果和业绩可能与前瞻性陈述中预计的结果存在重大差异，原因是。

Ukraine

乌克兰

–

Russia

俄罗斯

conflict and the conflict in the

冲突以及冲突在

Middle East

中东地区

on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes, the Company's ability to close the proposed public offering, and the risk that warrants issued in this offering will not be exercised for cash in the future.

关于计划中和正在进行的临床试验，与预测未来现金使用和为或有负债及业务运营所需储备的能力相关的风险和不确定性，是否有足够的财务和其他资源来满足业务目标和运营需求，早期临床前研究和临床试验的结果可能无法预测未来临床试验结果的事实，公司产品或候选产品目标市场的规模发生的任何变化，Immunic的知识产权所提供的保护和市场独占性，与药物开发和监管审批程序相关的风险以及竞争产品和技术变革的影响，公司完成拟议公开发行的能力，以及本次发行中发放的认股权证未来可能不会被行使以获取现金的风险。

A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned 'Risk Factors,' in the Company's Annual Report on Form 10-K for the fiscal year ended .

这些风险、不确定性及其他因素的进一步列表和描述，可参见公司截至本财年结束的年度报告 Form 10-K 中标题为“风险因素”的章节。

December 31, 2024

2024年12月31日

, filed with the SEC on

，提交给美国证券交易委员会（SEC）的日期是

March 31, 2025

2025年3月31日

, and in the Company's subsequent filings with the SEC. Copies of these filings are available online at

，并在公司随后向美国证券交易委员会提交的文件中。这些文件的副本可在线获取于

www.sec.gov

or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release..

或 ir.imux.com/sec-filings。本发布中包含的任何前瞻性陈述仅截至本发布之日作出。Immunic 免责声明不承担更新这些前瞻性陈述以反映在作出陈述之后发生的事件或情况的意图或义务。Immunic 明确否认对基于本新闻稿全部或部分内容采取或未采取的任何行动所引发的所有责任。

Contact Information

联系信息

Immunic, Inc.

Immunic有限公司

Jessica Breu

杰西卡·布劳

Vice President Investor Relations and Communications

副总裁，投资者关系与沟通

+49 89 2080 477 09

jessica.breu@imux.com

杰西卡·布劳@imux.com